Nephros – Consensus Indicates Potential 61.1% Upside

Broker Ratings

Nephros found using ticker (NEPH) now have 3 analysts in total covering the stock. The consensus rating is ‘Buy’. The target price ranges between 16 and 9.75 with the average target price sitting at 12.92. Given that the stocks previous close was at 8.02 this indicates there is a potential upside of 61.1%. The 50 day MA is 6.52 and the 200 day MA is 7.12. The market capitalisation for the company is $76m. Find out more information at: http://www.nephros.com

The potential market cap would be $122m based on the market concensus.

You can now share this on Stocktwits, just click the logo below and add the ticker in the text to be seen.

Share on Stocktwits

Nephros, a commercial-stage company, develops and sells liquid purification filters and hemodiafiltration (HDF) systems in the United States. It operates through two segments, Water Filtration and Renal Products. The company’s ultrafilters are used in dialysis centers for the removal of biological contaminants from water and bicarbonate concentrate; and in hospitals for the prevention of infection from waterborne pathogens, such as legionella and pseudomonas, as well as in military and outdoor recreation, commercial, and other healthcare facilities. It offers HDF systems for use in conjunction with a hemodialysis machine that enables nephrologists to provide HDF treatment to patients with end stage renal disease; hemodiafilters for use as dialyzers in hemodialysis treatment; and water filters to health care, food service, hospitality, and convenience store markets under the AETHER brand name. The company was founded in 1997 and is headquartered in South Orange, New Jersey.

Find more news, interviews, share price & company profile here for:

    Good news travels fast (but only if you make that happen). Share on:

    Twitter
    LinkedIn
    Facebook
    Email
    Reddit

      AIM All Share Index